Chondrial Therapeutics is a biotechnology company focused on developing treatments for Friedreich’s ataxia (FA). They recently announced that the first person has been treated in a Phase 1 clinical trial to assess the safety and tolerability of CTI-1601. People with FA have reduced amounts of protein called frataxin in their cells. CTI-1601 is a treatment that aims to deliver the frataxin protein to the cells of people with FA, and therefore treat the underlying cause of the condition.
Carol Ben-Maimon, MS, President and Chief Executive Officer of Chondrial Therapeutics said “CTI-1601 is designed to address the root cause of Friedreich’s ataxia – low levels of frataxin. The initiation of our Phase 1 clinical program was supported by positive preclinical data and is an important step forward for patients affected by FA, a devastating and progressive disease for which there is no cure”.
The trial is taking place in the US, and results are expected by the end of 2020. Read the full press release here.
Posted on 19/12/2019
